Compounding this, a new regulatory subpopulation of innate lymphoid cells (ILCs) named ILCregs, which expresses Id3 and produces IL-10, has recently been shown to modulate the inflammatory response33–35 and are thought to contribute to cancer progression and therefore, must also be overcome to empower cancer immunotherapies36. The gene discussed is IL10; the disease is cancer.